

Congress of the United States

House of Representatives

COMMITTEE ON OVERSIGHT AND ACCOUNTABILITY

2157 RAYBURN HOUSE OFFICE BUILDING

WASHINGTON, DC 20515-6143

MAJORITY (202) 225-5074
MINORITY (202) 225-5051

<https://oversight.house.gov>

MEMORANDUM

May 5, 2023

To: Members, Subcommittee on Health Care and Financial Services

From: Committee Staff

Re: Hearing titled “FDA Oversight Part II: Responsibility for the Infant Formula Shortage”

On **Thursday, May 11, 2023, at 2:00 p.m. ET, in room 2154 of the Rayburn House Office Building**, the Subcommittee on Health Care and Financial Services will host a hearing titled “FDA Oversight Part II: Responsibility for the Infant Formula Shortage.”

I. BACKGROUND:

On March 28, 2023, the Subcommittee on Health Care and Financial Services held an oversight hearing examining the causes and consequences of the 2022 nationwide shortage of powdered infant formula. That hearing highlighted the inadequacy of the U.S. Food and Drug Administration’s (FDA) inspection and supply chain monitoring processes. As the primary regulator of critical foods, including infant formula, FDA has a duty to ensure a safe and secure supply for American children and families.

II. HEARING PURPOSE:

The hearing will continue the Subcommittee’s investigation of the FDA’s response to the *cronobacter* outbreak at Abbott Nutrition’s powdered infant formula production facility and the subsequent nationwide shortage of infant formula.

III. WITNESS:

Susan T. Mayne, Ph.D.

Director, Center for Food Safety and Applied Nutrition
U.S. Food and Drug Administration